Sai Reddy - NCCR MSE

Sai Reddy

Department of Biosystems Science and Engineering (D-BSSE), ETH Zurich

Project Leader

Publications

D. M. Mason, S. Friedensohn, C. R. Weber, C. Jordi, B. Wagner, S. M. Meng, R. A. Ehling, L. Bonati, J. Dahinden, P. Gainza, B. CorreiaS. Reddy “Optimization of Therapeutic Antibodies by Predicting Antigen Specificity from Antibody Sequence Via Deep Learning“ Nat. Biomed. Eng. 2021. [DOI]
R. B. Di Roberto, R. Castellanos-Rueda, S. Frey, D. Egli, R. Vazquez-Lombardi, E. Kapetanovic, J. Kucharczyk, S. Reddy “A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced on-Target, Off-Tumor Activation“ Mol. Ther. 2020. [DOI]
T. Pesch, L. Bonati, W. Kelton, C. Parola, R. A. Ehling, L. Csepregi, D. Kitamura, S. Reddy “Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells“ Front. Immunol. 2019. [DOI]
C. R. Weber, D. M. Mason, S. M. Meng, V. Greiff, W. J. Kelton, S. Reddy, C. Parola “High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis“ Nucleic Acids Res. 2018, 46:7436-7449. [DOI]
S. Reddy “Reprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange“ Sci. Rep. 2017, 7:45775. [DOI]
M. Pogson, C. Parola, W. J. Kelton, P. Heuberger, S. Reddy “Immunogenomic engineering of a plug-and-(dis)play hybridoma platform“ Nat. Commun. 2016, 7:12535. [DOI]
Y. Cotelle, N. Chuard, S. Lascano, V. Lebrun, R. Wehlauch, N. Bohni, S. Lörcher, V. Postupalenko, S. Reddy, W. Meier, C. G. Palivan, K. Gademann, T. R. WardS. Matile “Interfacing Functional Systems“ Chimia 2016, 6:418. [DOI]
W. Kelton, T. PeschS. MatileS. Reddy “Surveying the Delivery Methods of CRISPR/Cas9 for ex vivo Mammalian Cell Engineering“ Chimia 2016, 6:439. [DOI]
M. Pogson, W. Kelton, S. Reddy “Microscale Technologies for High-Throughput Analysis of Immune Cells“ Microscale Technologies for Cell Engineering 2016:219-30. [DOI]
P. Muller, M. Kreuzaler, T. Khan, D. S. Thommen, K. Martin, K. Glatz, S. Savic, N. Harbeck, U. Nitz, O. Gluz, M. von Bergwelt-Baildon, H. Kreipe, S. Reddy, M. Christgen, A. Zippelius “Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade“ Sci. Transl. Med. 2015, 7:315ra188. [DOI]